Incidence of Opioid Overdose Among Patients Using ER/LA Opioid Analgesics Before and After Implementation of the Class-Wide Opioid Risk Evaluation and Mitigation Strategy

INTRODUCTION: The United States (US) Food and Drug Administration (FDA) required a Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics on 09 July 2012. METHODS: This study compared the incidence of opioid overdose before (July 2010-June 2012)...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Daina B, Cepeda, M Soledad, Holick, Crystal N, Knox, Caitlin, Desai, Vibha CA, Liu, Nianya, Vojjala, Shiva-Krishna, Lyons, Jennifer G, Wedin, Gregory P, Lanes, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970623/
https://www.ncbi.nlm.nih.gov/pubmed/32021405
http://dx.doi.org/10.2147/JPR.S219324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6970623/
https://www.ncbi.nlm.nih.gov/pubmed/32021405
http://dx.doi.org/10.2147/JPR.S219324

Ejemplares similares